Astrazeneca Share News (AZN)
AZN Share
AZN Share
AZN Share
AZN Share
AZN
AZN Share
AZN Level 2
AZN Live
AZN Broker
AZN Directors
AZN Financial
AZN
AZN Short
AZN
Last checked at -
(Alliance News) - Stock prices in London opened higher on Monday amid hopes of less aggressive monetary policy tightening by central banks, while Biffa shares fell after a delay to the publication of its annual results.
Read more(Alliance News) - AstraZeneca PLC said on Monday that its breast cancer treatments, Lynparza and Enhertu, have been recommended for approval in the EU.
Read more(Alliance News) - Stock prices in London are seen opening higher on Monday following a strong close in the US on Friday and a rally across Asian markets, amid gatherings of world leaders and central bankers at separate meetings in Europe this week.
Read more
(Sharecast News) - Drugmaker AstraZeneca said on Monday that Lynparza, its HER2-negative high-risk early breast cancer drug, has been recommended for marketing authorisation in the European Union after demonstrating "a statistically significant and clinically meaningful" improvement in invasive disease-free survival.
Read more
MANNHEIM, June 24 (Reuters) - Roche remains sceptical about investing more in antibody-drug conjugates (ADCs), which have been described as "guided-missile" cancer drugs, even as they attract heightened attention in the pharmaceutical industry.
Read moreMANNHEIM, June 24 (Reuters) - Roche remains sceptical about investing more in the field of antibody-drug conjugates (ADCs), which have been described as "guided-missile" cancer drugs due to their precision, even as the field attracts heightened attention in the pharmaceutical industry.
Read morePARIS/LONDON, June 24 (Reuters) - Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.
Read moreJune 23 (Reuters) - Valneva's COVID-19 vaccine was endorsed by the European Medicines Agency (EMA) on Thursday, although the French company's contract with the European Commission to supply the dose hangs in the balance.
Read more(Alliance News) - AstraZeneca PLC on Thursday reported strong results from phase III clinical trials for ALXN1840.
Read more(Sharecast News) - Analysts at Citi reiterated their 'buy' recommendation for shares of AstraZeneca following the release of the results of the DESTINY-Breast 04 clinical trial using its Enhertu treatment against metastatic breast cancer.
Read moreLONDON, June 22 (Reuters) - Leaders of the global scheme aiming to get COVID-19 vaccines to the world's poorest are pushing manufacturers including Pfizer and Moderna to cut or slow deliveries of about half a billion shots so doses are not wasted.
Read more(Alliance News) - Merck & Co Inc on Tuesday said its Lynparza drug, developed alongside AstraZeneca PLC, improved survival rates for some sufferers of prostate cancer.
Read more(Alliance News) - AstraZeneca PLC on Tuesday said eplontersen, its candidate for a form of hereditary polyneuropathy, demonstrated significant positive results in a phase 3 trial interim analysis.
Read more(Sharecast News) - Drugmaker AstraZeneca has received positive high-level results from an interim analysis of its NEURO-TTRansform Phase III trial on eplontersen, the group's hereditary transthyretin-mediated amyloid polyneuropathy drug candidate.
Read moreNEW YORK, June 17 (Reuters) - People infected with the earliest version of the Omicron variant of the coronavirus, first identified in South Africa in November, may be vulnerable to reinfection with later versions of Omicron even if they have been vaccinated and boosted, new findings suggest.
Read more
Last checked at